-
-
-
-
-
-
Patent Agency Ranking
-
-
公开(公告)号：KR1020120037613A
公开(公告)日：2012-04-20
申请号：KR1020100099169
申请日：2010-10-12
Applicant: 박사룡
Inventor： 박사룡
Abstract: PURPOSE: A novel type band-aid containing lysozyme without causing tolerance is provided to sterilize bacteria by hydrolyzing substances forming the cell membrane of the bacteria. CONSTITUTION: A novel type band-aid containing lysozyme includes a supporting body(1), a drug layer(2), and a releasing film(3). The supporting body includes an adhesive and a lysozyme hydrochloride layer. The lysozyme hydrochloride layer is formed by soaking a piece of gauze or cotton with a solution of lysozyme hydrochloride, or spreading the lysozyme hydrochloride solution on the gauze or the cotton.
Abstract translation: 目的：提供一种不引起耐受性的含有溶菌酶的新型助剂，通过水解形成细菌细胞膜的物质对细菌进行灭菌。 构成：含有溶菌酶的新型助剂包括支撑体（1），药物层（2）和脱模膜（3）。 支撑体包括粘合剂和盐酸溶菌酶层。 通过将一块纱布或棉布与溶菌酶盐酸盐溶液浸泡，或将溶菌酶盐酸盐溶液铺展在纱布或棉布上形成盐酸溶菌酶层。
-
公开(公告)号：KR1020110050881A
公开(公告)日：2011-05-17
申请号：KR1020090107454
申请日：2009-11-09
Applicant: 박사룡
Inventor： 박사룡
IPC: C07D403/12 , C07D401/12 , C07D403/02
Abstract: PURPOSE: A composition containing non-hygroscopic acid addition salt of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid is provided to ensure anti-histamine activity and anti-allergic activity. CONSTITUTION: A novel pivalate of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid is a compound I and is stable without hygroscopicity. A pharmaceutical composition contains the novel pivalate as an active ingredient. A method for preparing the pivalate comprises: a step of dissolving a compound of structural formula I in an organic solvent of methyl acetate, ethyl acetate, chloroform, benzene, acetonitrile, methanol, and ethanol; a step of reacting with toluic acid or toluene sulfonic acid; and a step of concentrating and crystallizing.
Abstract translation: 目的：提供含（S）-4- [4 - [（4-氯苯基）（2-吡啶基）甲氧基]哌啶子基]丁酸的非吸湿性酸加成盐的组合物，以确保抗组胺活性和抗过敏 活动。 构成：（S）-4- [4 - [（4-氯苯基）（2-吡啶基）甲氧基]哌啶子基]丁酸的新颖的新戊酸是化合物I，并且在没有吸湿性的情况下是稳定的。 药物组合物含有新戊酸酯作为活性成分。 一种制备新戊酸的方法包括：将结构式I的化合物溶于乙酸甲酯，乙酸乙酯，氯仿，苯，乙腈，甲醇和乙醇的有机溶剂中的步骤; 与甲苯甲酸或甲苯磺酸反应的步骤; 和浓缩和结晶的步骤。
-
公开(公告)号：KR1020090057538A
公开(公告)日：2009-06-08
申请号：KR1020070124156
申请日：2007-12-03
Applicant: 박사룡
Inventor： 박사룡
CPC classification number: A61K31/41 , A61K31/167 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/44 , A61K31/4422 , A61K31/4965 , A61K31/549 , A61K31/635
Abstract: A composition for treating hypertension using an angiotensin II antagonist, calcium antagonist and diuretic is provided to lessen use amount, side effect and blood pressure. A composition of an oral therapeutic agent for treating hypertension comprises an angiotensin II antagonist, calcium antagonist and diuretics. The angiotensin II antagonist is selected valsartan, telmisartan, candesartan cilexetil, irbesartan, olmesartan medoxomil, losartan K, eprosartan and telmisartan. The calcium antagonist is selected from nipedipine, isradipine, nicardipine HCl, felodipine, manidipine, lacidipine, benidipine HCl, cilnidipine, lercanidipine HCl, barnidipine HCl, nilvadipine, nitrendipine, and diltiazem. The diuretic is bendroflumethiazide, benzthiazide, chlorothiazide, hydrochlorothiazide, chlorthalidone, indapamide, matolazone, quinethazone, cyclothiazide, furosemide, and indapamide.
Abstract translation: 提供使用血管紧张素II拮抗剂，钙拮抗剂和利尿剂治疗高血压的组合物，以减少使用量，副作用和血压。 用于治疗高血压的口服治疗剂的组合物包含血管紧张素II拮抗剂，钙拮抗剂和利尿剂。 血管紧张素II拮抗剂选择缬沙坦，替米沙坦，坎地沙坦酯，厄贝沙坦，奥美沙坦酯，洛沙坦K，依普罗沙坦和替米沙坦。 钙拮抗剂选自下列药物：钙ed啶，伊拉地平，盐酸尼卡地平，非洛地平，马尼地平，拉西地平，盐酸贝尼地平，西尼地平，氯卡地平，盐酸巴尼地平，尼伐地平，尼群地平和地尔硫卓。 利尿剂是四氟嘧啶，苯噻嗪，氯噻嗪，氢氯噻嗪，氯噻酮，吲达帕胺，托洛沙酮，喹三唑，环噻嗪，呋塞米和吲达帕胺。
-
-
-
-
-
-
-
-
-
Search Results
77
records
(took 0.016 seconds)
